The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib. Read more about The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. Read more about Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Read more about Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study. Read more about Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.
Clinical features associated with thrombotic events in children with myeloproliferative neoplasms. Read more about Clinical features associated with thrombotic events in children with myeloproliferative neoplasms.
Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia. Read more about Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia.
Clinical characteristics of cytomegalovirus-positive pediatric acute lymphoblastic leukemia at diagnosis. Read more about Clinical characteristics of cytomegalovirus-positive pediatric acute lymphoblastic leukemia at diagnosis.
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Read more about Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
Diagnostic work-up for severe aplastic anemia in children: Consensus of the North American Pediatric Aplastic Anemia Consortium. Read more about Diagnostic work-up for severe aplastic anemia in children: Consensus of the North American Pediatric Aplastic Anemia Consortium.
Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study. Read more about Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study.
